Calcium acetate anhydrous is indicated for the control of hyperphosphatemia in patients with chronic kidney disease (CKD), particularly those on dialysis. Its key advantage is effective phosphate binding in the gastrointestinal tract, reducing phosphate absorption from food and helping maintain optimal serum phosphate levels. Proper phosphate control is essential to prevent complications such as secondary hyperparathyroidism, vascular calcification, and bone disorders. Compared to some alternatives, calcium acetate provides strong phosphate-binding capacity with relatively lower calcium load, allowing effective management with appropriate dosing. Oral administration with meals ensures targeted action where phosphate absorption occurs. It is a widely used and reliable option in nephrology practice for long-term management of mineral and bone disorders in CKD patients.